Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $2.63 billion. The enterprise value is $3.40 billion.
| Market Cap | 2.63B |
| Enterprise Value | 3.40B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 98.29 million shares outstanding. The number of shares has increased by 4.22% in one year.
| Current Share Class | 98.29M |
| Shares Outstanding | 98.29M |
| Shares Change (YoY) | +4.22% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 3.60% |
| Owned by Institutions (%) | 103.06% |
| Float | 92.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.67 |
| Forward PS | 3.10 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.73
| Current Ratio | 1.73 |
| Quick Ratio | 1.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.22% |
| Return on Invested Capital (ROIC) | -31.77% |
| Return on Capital Employed (ROCE) | -57.85% |
| Weighted Average Cost of Capital (WACC) | 5.69% |
| Revenue Per Employee | $522,976 |
| Profits Per Employee | -$427,425 |
| Employee Count | 1,371 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 16.42 |
Taxes
In the past 12 months, RARE has paid $4.00 million in taxes.
| Income Tax | 4.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.69% in the last 52 weeks. The beta is 0.31, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -2.69% |
| 50-Day Moving Average | 27.69 |
| 200-Day Moving Average | 26.78 |
| Relative Strength Index (RSI) | 47.06 |
| Average Volume (20 Days) | 1,943,499 |
Short Selling Information
The latest short interest is 13.44 million, so 13.67% of the outstanding shares have been sold short.
| Short Interest | 13.44M |
| Short Previous Month | 16.22M |
| Short % of Shares Out | 13.67% |
| Short % of Float | 14.60% |
| Short Ratio (days to cover) | 4.24 |
Income Statement
In the last 12 months, RARE had revenue of $717.00 million and -$586.00 million in losses. Loss per share was -$5.83.
| Revenue | 717.00M |
| Gross Profit | -149.00M |
| Operating Income | -498.00M |
| Pretax Income | -582.00M |
| Net Income | -586.00M |
| EBITDA | -495.17M |
| EBIT | -528.17M |
| Loss Per Share | -$5.83 |
Balance Sheet
The company has $292.00 million in cash and $1.20 billion in debt, with a net cash position of -$766.00 million or -$7.79 per share.
| Cash & Cash Equivalents | 292.00M |
| Total Debt | 1.20B |
| Net Cash | -766.00M |
| Net Cash Per Share | -$7.79 |
| Equity (Book Value) | -284.00M |
| Book Value Per Share | -2.96 |
| Working Capital | 255.00M |
Cash Flow
In the last 12 months, operating cash flow was -$485.00 million and capital expenditures -$4.00 million, giving a free cash flow of -$489.00 million.
| Operating Cash Flow | -485.00M |
| Capital Expenditures | -4.00M |
| Depreciation & Amortization | 33.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -489.00M |
| FCF Per Share | -$4.98 |
Margins
Gross margin is -20.78%, with operating and profit margins of -69.46% and -81.73%.
| Gross Margin | -20.78% |
| Operating Margin | -69.46% |
| Pretax Margin | -81.17% |
| Profit Margin | -81.73% |
| EBITDA Margin | -69.04% |
| EBIT Margin | -73.64% |
| FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.22% |
| Shareholder Yield | -4.22% |
| Earnings Yield | -22.25% |
| FCF Yield | -18.56% |
Analyst Forecast
The average price target for RARE is $52.84, which is 97.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $52.84 |
| Price Target Difference | 97.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (3Y) | 22.87% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -4.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.78 |
| Piotroski F-Score | 3 |